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Abstract
PLAN QUALITY AND ISOTOXIC DOSE ESCALATION INVESTIGATION USING A 0.35T MR-LINAC SYSTEM IN
ABLATIVE 5-FRACTION STEREOTACTIC MAGNETIC RESONANCE-GUIDED RADIATION THERAPY (MRGRT)
FOR PRIMARY PANCREATIC CANCER
By Robert Hawranko, BS

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University

Virginia Commonwealth University, 2020

Major Director: William Y. Song, Ph.D., Associate Professor, Department of Radiation Oncology

This study investigates plan quality generated by an MR-Linac (MRL) treatment planning system (TPS) for
5-fraction stereotactic body radiation therapy (SBRT) of primary pancreatic cancer (PCa). In addition, an
isotoxic dose escalation was investigated with the MRL TPS based on the stereotactic MR-guided
adaptive radiation therapy (SMART) trial constraints. A clinical workflow was developed for adaptive and
non-adaptive treatments with the MRL, on which a time-driven activity-based costing (TDABC) analysis
was performed to quantify clinical efficacy. Fifteen Pca patients previously treated with a conventional
Linac were retrospectively re-planned for this study. Three plans were generated for each patient: using
the original prescription dose (PD) and organ at risk (OAR) constraints (Plan 1), following SMART trial’s
OAR constraints but with the original PD (Plan 2), and, starting with Plan 2, following an isotoxic dose
escalation strategy where dose was escalated until any one of the SMART trial’s OAR constraints
reached its limit (Plan 3). Conformity index (CI) and the ratio of the 50% isodose volume to PTV (R50%)
conformity metrics were calculated for all 45 MRL plans, in addition to standard dose-volume indices. 45
MR-Linac plans were created which met their respective dosimetric criteria described above. For Plan 1,
the MR-Linac TPS successfully achieved equivalent or lower OAR doses while maintaining prescribed PTV
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coverage, for the 15 plans. Maximum dose to the small bowel was reduced on average by 4.97 Gy
(range: 1.11-10.58 Gy). For Plan 2, the MR-Linac TPS successfully met all SMART trial OAR constraints
while maintaining equivalent PTV coverage. For Plan 3, the MR-Linac TPS was able to escalate the
prescription dose from the original 25-33 Gy by, on average, 36 Gy (range: 15-70 Gy), and, dose to the
PTV has been successfully escalated to at least 50 Gy for all 15 plans. These achievements were made
possible in part due to the omission of the ITV afforded by the MR-Linac’s real-time target tracking
technology and sharper dose penumbra due to its unique dual-focus MLC design. The 0.35T MRL TPS
can generate plans that are equivalent to conventional Linac-based plans for SBRT of Pca. Through
analyzing Plan 2 and 3 strategies, and due to the real-time target localization capabilities of the MRL
system, increased OAR sparing and/or target dose escalation are possible.
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1. Introduction
The American Cancer Society reported in 2000 that pancreatic cancer had a 5-year overall survival rate
of less than 5%, even with aggressive management, and estimated it to cause 30,000 deaths per year in
just the United States [1]. Findings from a more recent review of pancreatic cancer was published by the
American Medical Association in 2021 gathered from 43 randomized clinical trials, 85 meta-analyses,
and 171 systematic reviews showed the 5-year survival rate is approaching 10% with approximately
60,000 novel cases per calendar year [2]. Although the 5-year overall survival has almost doubled over
the last two decades, pancreatic cancer continues to hold its place as the lowest survival rate of any
cancer. With current data indicating represents an increase in incidence of 0.5-1.0% per year, pancreatic
cancer is projected to become the second-leading-cause of death from cancer by the year 2023 [2].
Currently the only curative treatment for pancreatic cancer is surgical resection, but only 15-20% of
patients have resectable disease. While most unresectable disease is metastatic, 50-55% of total
instance, there are a significant number of cases, 30-35% of total instance, that are considered to be
locally advanced. 2 In the case of unresectable disease, radiation therapy offers palliative benefits such
as pain relief and is often used in combination with other adjuvant therapies but is not used in an
ablative capacity due to uncertainty in dose to normal tissue as a result of motion. The first radiation
therapy treatment for pancreatic consisted of a conservative dose to the pancreas over a hyperfractionated regimen; this technique is known as conventionally fractionated radiation therapy (CFRT).
Stereotactic body radiation therapy (SBRT) is used to increase outcome for pancreatic cancer patients
undergoing an adjuvant radiation treatment. A review of 1,147 patients treated with adjuvant external
beam radiation therapy between the years of 2002 and 2014 revealed that the most common CFRT
consisted of 50.4 Gy in 28 fractions delivered to the tumor and the most common SBRT consisted of 30
Gy in 5 fractions delivered to the tumor, and analysis of the data showed a statistical significance
(P<0.05) in 2-year overall survival for SBRT over CFRT, 26.9% and 13.7% respectively [3]. The benefits of
SBRT for unresectable pancreatic cancer is supported in literature, but the technique is still restrained by
the possibility of normal structure encroachment into the treatment site, thus the total dose to the
target volume is kept low enough to prevent early toxicity. The pancreas is particularly susceptible to
motion due to its location in the abdomen. Peristalsis, breath motion, and day-to-day irregularities along
with the extreme radiosensitivity of the gastrointestinal tract have trained physicists and oncologists to
err on the side of caution when planning pancreatic SBRT. The introduction of onboard imaging,
beginning with cone-beam computed tomography (CBCT) integrated with linear accelerator (Linac), was
the first step toward solving this problem by allowing an on-table visualization of the daily anatomy, but
CBCT images are not the best modality for soft tissue visualization and they add ionizing radiation that
patients receive. The most recent development in onboard imaging comes in the form of magnetic
resonance-guided radiation therapy (MRgRT). This technology has significant promise due to several
factors: superior soft tissue contrast, real time anatomic information, active target tracking, and beam
gating.
2. Materials and Methods
A collection of 15 PCa patients that were previously treated with a conventional C-Arm Linac were
selected to be retrospectively re-planned for the 0.35T MR-Linac (MRL) using the novel MRL’s
commercial treatment planning system (TPS). Three categories of plan were generated for each patient.
The criteria for a patient to be selected for re-planning was that they had completed all external beam
radiation treatment and that there was a 4DCT taken at the time of simulation. Plan 1 was created using
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the original prescription dose to the tumor volume and normal tissue dose constraints as used when the
patient was planned and treated with a conventional TPS and Linac. A patient was randomly selected
from the group and the data for plan 1 is displayed in Figure 1A & 1D, which shows isodose lines at
100%, 50%, and 40% of Rx dose, which for this case is 30 Gy. Additionally, shown in this figure is the
DVHs for critical organs at risk (OARs) such as small bowl, duodenum, stomach, GTV, and PTV. Plan 2
was created using the original plan’s prescription dose to the tumor volume but following a novel set of
normal tissue dose constraints that were developed in a leading publication on stereotactic MR-guided
adaptive radiation therapy, henceforth referred to as the SMART trial.4 The organ at risk (OAR)
constraints outlined by the SMART trial can be found in Table 1.A collection of 15 PCa patients that were
previously treated with a conventional C-Arm Linac were selected to be retrospectively re-planed for the
0.35T MRL using the novel MRL TPS. Three categories of plan were generated for each patient. The
criteria for a patient to be selected for re-planning was that they had completed all external beam
radiation treatment and that there was a 4DCT taken at the time of simulation. Plan 1 was created using
the original prescription dose to the tumor volume and normal tissue dose constraints as used when the
patient was planned and treated with the conventual treatment planning system and Linac. Plan 2 was
created using the original plan’s prescription dose to the tumor volume but following a novel set of
normal tissue dose constraints that were developed in a leading publication on stereotactic MR-guided
adaptive radiation therapy, henceforth referred to as the SMART trial [4]. The organ at risk constraints
outlined by the SMART trial can be found in Table 1. The idea behind Plan 2 is to create a “robust” plan,
which in effect means a plan that can remain within normal tissue constraints without necessitating
adaptation to daily anatomical changes. Plan 3 was created by taking plan 2, then following an isotoxic
dose escalation strategy wherein dose was escalated until any one of the SMART trial’s OAR constraints
reached its limit.
Table 1. Depicts OAR dose constraints as used in the SMART trial.
Organ at Risk

Dose Constraint
V35 < 0.5 mL

Stomach, duodenum, small bowel
V40 < 0.03 mL
V38 < 0.5 mL
Large bowel
V43 < 0.03 mL
Kidneys

Dmean< 10 Gy

Liver

Dmean < 15 Gy

Spinal cord

V25 < 0.03 mL

The idea behind Plan 2 is to create a “robust” plan, which in effect means a plan that can remain within
the normal tissue constraints listed in Table 1 without necessitating adaptation to daily anatomical
changes. The same patient that was randomly selected for plan 1 was also displayed for plan 2 in Fig. 1B
and 1E, which shows isodose lines at 100%, 50%, and 40% of original Rx dose, which for this case is 30
Gy. Additionally, shown in this figure is the DVH for critical OARs such as small bowel, duodenum,
stomach, GTV, and PTV. Plan 3 was created by taking plan 2, then following an isotoxic dose escalation
8

strategy wherein dose was escalated until any one of the SMART trial’s OAR constraints reached its limit.
The conventional Linac plans (25-33 Gy in 5 fractions) accounted for respiratory motion by creating an
ITV that encompassed the GTV’s motion range, based on a 4DCT study before applying a PTV margin of 5
mm. Dose calculations were performed on a derived average intensity projection image. For the 3 plan
types generated with the MRL TPS, the GTV was defined on the 0% phase and was expanded uniformly
in all directions with a PTV margin of 3 mm. The creation of ITV is unnecessary in this case due to the
MRL’s real-time target tracking and gating technology, where in mild inspiration breath-hold (10%
phase) treatments are allowed and implemented clinically. The same patent that was randomly selected
for plans 1&2 above was also displayed for plan 3 in Figure 1C & 1F, which shows isodose lines at 100%,
50%, and 40% of escalation dose, which for this case is 77 Gy. Additionally, shown in this figure are the
DVHs for OARs such as small bowel 0%, duodenum 0%, stomach 0%, GTV 0%, and PTV_high. It is
apparent to the observer that it is more difficult to create a conformal plan as dose is escalated, which
can be seen in the form of the anisotropic shapes of the lower isodose lines in figure 2C. In that specific
case, dose is being pushed out to the chest wall in order to avoid exceeding constraints on stomach. This
poses the question: are the constraints that are currently tracked sufficient?
As mentioned above, an additional planning structure called PTV_high was created for Plan 3 and is
defined as the PTV minus a 3 mm expansion of the OARs in close proximity to the PTV. A pass/fail
criterion for Plan 3 evaluation is defined such that all of the following must be true: all SMART trial
normal tissue dose constraints are met, PTV maintains 95% of original prescription dose, PTV_high
maintains coverage of 95% of escalated dose, and PTV_high conformity index (Eq 1, 2) is less than or
equal to 1.2. A typical strategy for creating Plan 3 was to begin by trying to escalate dose to 50 Gy to
95% of the PTV_high volume. If it is not possible or reasonably feasible, dose to the PTV_high is
decreased at 5 Gy increments and re-evaluated at each iteration. If the 50 Gy escalation meets the
criteria, keep escalating dose to the PTV_high. Depending on how easily the previous plan met the
criteria, this jump can be made by 5 or 10 Gy). This process is iterated until the plan met all of the Table
1 criteria, and the plan with the highest satisfactory escalation is accepted. Plan 3 was inspired by a
growing body of literature that is correlating high dose, low fraction treatment with increased local
control in PCa. A comprehensive review of SBRT of the abdomen and pancreas was performed by the
HyTEC group, the results of which lend strong support to increased local control after one year with
hypofractionation [5]. Not only is there a positive correlation with hypofractionation, but data trends
also suggest local control increases with dose escalation [5,6]. Local control is in of itself a positive
outcome and justification for further study into isotoxic dose escalation, but recent studies have now
started to build a case that increased local control leads to increased overall survival [6]. Indices for
maximum and mean dose volume was calculated for several OARs on Plan 1 and was analyzed against
the corresponding values from the original plan created for the patient on the conventional TPS.
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Figure 1. Depicts a sample patient picked from the group for plan 1 (A & D), Plan 2 (B & E), and Plan 3 (C
& F). Note that for this sample, plan 3 escalation dose was 77 Gy to 95% of PTV_High.
Comparison of mean and max dose to typical OARs allows comparison of the conventional TPS plans,
which were created as volumetric modulated arc therapy (VMAT), and the MRL TPS plans, which were
created as step-and-shoot IMRT. This analysis was not extended to plans 2 and 3 due to these plans
having a novel set of normal tissue constraints and or prescribed dose to target, which would make the
juxtaposition against originally planned parameters incoherent. It was necessary to use an alternate
analysis on plans two and three against the conventional plan by comparing relative values such as
conformity index (CI) and R50 conformity metrics. Equation 1, given as:
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𝑪𝑰𝑷𝒍𝒂𝒏 𝟐 =

𝑽𝑹𝑿 𝒊𝒔𝒐𝒅𝒐𝒔𝒆
𝑽𝑷𝑻𝑽

(1)

defines how CI is calculated for Plan 2 where VRX isodose is the volume of the prescription isodose line and
VPTV is the volume of the PTV. Equation 2, given as:
𝑪𝑰𝑷𝒍𝒂𝒏 𝟑 =

𝑽𝑬𝒙𝒄𝒂𝒍𝒂𝒕𝒊𝒐𝒏 𝒊𝒔𝒐𝒅𝒐𝒔𝒆
𝑽𝑷𝑻𝑽_𝒉𝒊𝒈𝒉

(2)

defines how CI is calculated for Plan 3 where VExcalation isodose is the volume of the dose that the plan was
escalated to and isodose line and VPTV_high is the volume of the PTV_high. Equation 3, given as:
𝑪𝑰𝑷𝒍𝒂𝒏 𝟑 =

𝑽𝑬𝒙𝒄𝒂𝒍𝒂𝒕𝒊𝒐𝒏 𝒊𝒔𝒐𝒅𝒐𝒔𝒆
𝑽𝑷𝑻𝑽_𝒉𝒊𝒈𝒉

(3)

defines how R50 is calculated for Plan 2 where V0.5 RX isodose is the volume of the isodose line made by half
of the prescription dose and VPTV is the volume of the PTV. Equation 4, given as:
𝑹𝟓𝟎𝒑𝒍𝒂𝒏 𝟑 =

𝑽𝟎.𝟓 𝑬𝒔𝒄𝒂𝒍𝒂𝒕𝒊𝒐𝒏 𝒊𝒔𝒐𝒅𝒐𝒔𝒆
𝑽𝑷𝑻𝑽_𝒉𝒊𝒈𝒉

(4)

defines how R50 is calculated for Plan 3 where V0.5 RX isodose is the volume of the isodose line made by half
of the escalation dose and VPTV_high is the volume of the PTV_high. A question was posed above that are
the constraints that are currently tracked sufficient. One possible answer is to examine lower isodose
lines than conventional practice uses, such as looking at R20 for the escalation plan rather than R50.
In addition to a statistical analysis of plans created, a process map was created to chart simulation,
nonadaptive, and adaptive treatment workflows, which can be found in Figures 1, 2, and 3 respectively.
An analysis of the process map was done through a time-driven activity-based costing (TDABC) method
in order to gauge quality and cost of treatment on the MRL as well as inform process improvement.
TDABC works by breaking down a technology into a step by step workflow, identifying which personnel
interact with the workflow and for how long. A value is assigned to each individual’s time, and from this
a cost analysis of the technology is derived. Our institution began treatment of patients on the MRL as of
February 2022, and as such there was a limited amount of temporal data for our specific workflows. The
data was tracked internally though log sheets that broke down into the different steps shown in the
process map. To quantify the cost involved with each personnel involved in the treatment workflow, a
capacity cost rate (CCR) was calculated. In this study, CCR was determined by taking the average salary
of the personnel and dividing by the time worked. The salary data was taken from ZipRecruiter.com and
the time worked per year was determined using the total number of working days in 2021, i.e. 261 days,
minus paid time off days, 43 according to VCU Health public data, then converting into the unit of
minutes. This data is displayed in Table 2.
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Table 2: Depicts the capacity cost rate information in USD for personnel involved in the MRL workflows.
*salary information for medical physics residents taken from publicly available VCU Health system house
staff data for the 2021-2022 year.
Personnel

Virginia Avg. Salary [USD]

Cost Rate [USD/min]

Receptionist

30,545.00

0.292

Radiation
Therapist

78,886.00

0.754

Radiation
Oncologist

210,800.00

2.015

Dosimetrist

115,428.00

1.103

Medical
Physicist

173,178.00

1.655

Resident
Medical
Physicist*

61,470.00

0.587

Note that these figures are based solely on average salary per year in Virginia as according to a leading
salary reporting service, and do not include bonuses or fringe benefits. Included in Table 2 is the cost
rate description for a resident medical physicist, despite this position not appearing in any of the
workflows. This data is included due to the medical physics resident performing IMRT QA in our
department. For all intents and purposes this activity can be thought of as a single step between the
simulation and planning workflow and either of the treatment delivery workflows, and on average takes
30 minutes to complete.
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Simulation and Planning
Evaluation of
Eligibility for
Treatment
5-10 min

Check-in
Patient
2-3 min

MRI Safety
Check
Performed and
Patient Prep
15-30 min

Initial Setup

5-15 min

MR Image
Acquisition,
Patient
Localization,
Couch Shift
10-15 min

Legend
Radiation Oncologist
Receptionist

Plan Review
and Approval

Prescription
Review and
Approval

Plan Creation

Radiation Therapist
Dosimetrist

5 min

5-10 min

Medical Physicist

30-60 min

Target
Delineation,
Cine Setup,
and Acquisition
5-10 min

Total Time: 80-160 min

Figure 2: depicts process map for MRgRT simulation. The times depicted are approximated from data
gathered by VCU health staff.

Non-adaptive Treatment
Check-in
Patient
5 min

MRI Safety
Check
Performed and
Patient Prep
15-30 min

Initial Setup

5-15 min

MR Image
Acquisition,
Patient
Localization,
Couch Shift
5-40 min

Legend
Radiation Oncologist

Treatment
Delivery

Receptionist
Radiation Therapist

10-20 min

Dosimetrist
Medical Physicist

Total Time: 40-110 min

Figure3. Depicts process map for MRgRT simulation. The times depicted are approximated from data
gathered by VCU health staff.
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Adaptive Treatment
Check-in
Patient
5 min

MRI Safety
Check
Performed and
Patient Prep
15-30 min

Initial Setup

5-15 min

MR Image
Acquisition,
Patient
Localization,
Couch Shift
5-40 min

Legend
Radiation Oncologist
Receptionist

Treatment
Delivery

Radiation Therapist
Dosimetrist

10-35 min

Plan
Evaluation,
QA, and
Approval
5 min

Medical Physicist

Rule
Application,
Dose
Prediction,
Re-optimization

5 min

Contouring,
Plan
Propagation
18-31 min

Total Time: 68-156 min

Figure 4. Depicts a process map for non-adaptive MRgRT. The times depicted are approximated from
data gathered by VCU health staff.
3. Results
Forty-five MRL plans were created which met their respective dosimetric criteria described above. For
Plan 1, a statistical analysis of maximum and mean dose common OARs was carried out. A two tailed ttest (α = 0.05) failed to reject the null hypothesis that mean dose was no different for Plan 1 than for the
conventional plan for spinal cord (p = 0.16), stomach (p = 0.49), duodenum (p = 0.48), and small bowel
(p = 0.48). Further analysis showed that another two tailed t-test (α = 0.05) failed to reject the null
hypothesis that maximum dose was no different for Plan 1 than for the conventional plan for spinal cord
(p = 0.10), stomach (p = 0.48), duodenum (p = 0.47), and small bowel (p = 0.41). For Plan 2, the MRL TPS
successfully created robust plans that met, without pushing, all SMART trial normal tissue constraints
while maintaining equivalent PTV coverage. Plan 2 had an average CI of 1.05 (range: 0.98-1.24) and
average R50 of 3.81 (range: 3.32-5.07). For Plan 3, the MRL TPS was successful in escalating the
prescription dose from the original 25-33 Gy by, on average, 30 Gy (range: 15-70 Gy). Additionally, plan
3 had an average CI of 1.13 (range: 0.99-1.40) and average R50 of 4.50 (range: 3.29-9.67). Dose to the
PTV had been successfully escalated to at least 50 Gy for all dose escalation plans, much beyond
conventional fractionation of PCa SBRT, and it was even possible to escalate dose to extreme values in
patients with optimal normal tissue geometry. These achievements were made possible in part by the
omission of an ITV. The creation of an ITV was deemed unnecessary due to the MRL’s real-time target
tracking and gating technology along with a mild inspiration breath-hold treatment protocol. In addition
to omission of ITV, the dual-focus MLC provides a significant improvement in penumbra, and thus
contributes to the viability of dose escalation.
Through a TDABC analysis method, workflows have been generated that detail the personnel
that interact with them and the extent of their involvement. Analysis of the simulation process (Figure 1)
has shown that at least 5 types of staff interact directly with the process, the extent of which totals 80160 minutes. The resulting personnel cost for simulation and planning was based on the average time
spent per activity and totaled $129.17 USD. The nonadaptive treatment workflow (Figure 2) directly
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involves two types of staff and ranges from 40-110 minutes. The resulting personnel cost for the nonadaptive treatment was based on average time spent per activity and totaled $71.12 USD. The adaptive
workflow (Figure 3) is unsurprisingly more involved than that of the previous, and as such it involves
four separate roles and takes between 68 and 156 minutes. The resulting personnel cost for adaptive
treatment was based on the average time spent per activity and totaled $109.70 USD. Since each
treatment is always predicated by simulation and planning, the total personnel cost for simulation,
planning, and treatment is the sum of the two respective procedures. For non-adaptive planning, the
end-to-end personnel cost is $200.29 USD. For adaptive planning, the end-to-end cost is $238.87 USD.
An additional intermediate step for patients receiving treatment on the MRL is a CT simulation to
provide electron density information required for dose calculation in planning. This was not accounted
for in this study due to the authors choice to focus solely on costing from personnel on the MRL machine
only.

Table 3: Depicts the results of the TDABC analysis of the personnel cost associated with the simulation
and planning workflow.
Personnel

Average Time Spent
on Activity [min]

Cost [USD]

Receptionist

5

1.46

Radiation Therapist

52.5

39.58

Radiation Oncologist

15

30.22

Dosimetrist

45

49.64

Medical Physicist

5

8.27

Total Cost:

129.17
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Table 4: Depicts results of the TDABC analysis of personnel cost associated with the non-adaptive
treatment workflow.
Personnel

Average Time Spent
on Activity [min]

Cost [USD]

Receptionist

5

0.73

Radiation Therapist

70

52.77

Resident Medical
Physicist

30

17.62

Total Cost:

71.12

Table 1: Depicts results of the TDABC analysis of personnel cost associated with the adaptive treatment
workflow.
Personnel

Average Time Spent
on Activity [min]

Cost [USD]

Receptionist

5

1.46

Radiation Therapist

82.5

62.20

Radiation Oncologist

24.5

20.15

Medical Physicist

5

8.27

Resident Medical
Physicist

30

17.62

Total Cost:

109.70

4. Discussion and Conclusion
The 0.35T MRL TPS can successfully generate plans that achieved equivalent OAR doses to those
generated by conventional Linac-based treatments while maintaining prescribed PTV coverage. Through
analyzing Plan 2 and 3 strategies, and due to the real-time target localization capabilities of the MRL
system, increased OAR sparing and/or target dose escalation were found to be possible. The MRL
system has proven, in this study, to be an effective platform for creating robust conventionally
fractionated plans as well as plans that safely escalate doses where such is anticipated to translate to
possible clinical benefit for PCa patients. These achievements were made possible due to the MRL’s
superior soft tissue contrast, real-time target tracking with beam gating, and sharper dose penumbra
from its unique dual-focus MLC design. A TDABC analysis was carried out based on workflows for
simulation and planning, non-adaptive treatments, and adaptive treatments as well as a capacity cost
16

rate determination for involved personnel. This analysis shows a 19.3% increase in personnel cost for
adaptive treatment over non-adaptive treatment. Our next focus is to streamline the isotoxic dose
escalation planning workflow for clinical implementation as well as to explore various novel treatment
strategies that play to the benefit of MRgRT.

Funding: This research was funded by Value and Efficiency Teaching and Research (VETAR) Grant,
Virginia Commonwealth University (VCU) Health.
Institutional Review Board Statement: Approved from VCU Health.
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